A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex

International Journal of Neuropsychopharmacology

Volumn 16, Issue 2, 2013, Pages 477-483

  Perreault, Melissa L ^a,b   Jones Tabah, Jace ^a,b   O'Dowd, Brian F ^a,b   George, Susan R ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Akt; BDNF; D5 receptor; dopamine; GSK 3 ; prefrontal cortex

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 5 RECEPTOR; GLUTAMATE DECARBOXYLASE 67; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; SERINE; THREONINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE DELETION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANALYSIS OF VARIANCE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DOPAMINE AGONISTS; GENE EXPRESSION REGULATION; GLUTAMATE DECARBOXYLASE; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; SIGNAL TRANSDUCTION;

EID: 84875955170     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000685     Document Type: Article

References (25)

1. Alimohamad H, Rajakumar N, Seah YH, Rushlow W (2005). Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biological Psychiatry 57, 533-542.
2. Beaulieu JM (2012). A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. Journal of Psychiatry and Neuroscience 37, 7-16.
3. Berglind WJ, Whitfield Jr TW, LaLumiere RT, Kalivas PW, et al. (2009). A single intra-PFC infusion of BDNF prevents cocaine-induced alterations in extracellular glutamate within the nucleus accumbens. Journal of Neuroscience 29, 3715-3719.
4. Cotrufo T, Viegi A, Berardi N, Bozzi Y, et al. (2003). Effects of neurotrophins on synaptic protein expression in the visual cortex of dark-reared rats. Journal of Neuroscience 23, 3566-3571.
5. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, et al. (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nature Genetics 36, 131-137.
6. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, et al. (2004). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berlin) 174, 3-16.
7. Hasbi A, Fan T, Alijaniaram M, Nguyen T, et al. (2009). Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proceedings of the National Academy of Sciences USA 106, 21377-21382.
8. Hashimoto T, Bergen SE, Nguyen QL, Xu B, et al. (2005). Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. Journal of Neuroscience 25, 372-383.
9. Jin LQ, Goswami S, Cai G, Zhen X, et al. (2003). SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. Journal of Neurochemistry 85, 378-386.
10. Kutiyanawalla A, Promsote W, Terry A, Pillai A (2011). Cysteamine treatment ameliorates alterations in GAD67 expression and spatial memory in heterozygous reeler mice. International Journal of Neuropsychopharmacology 22, 1-14.
11. Lee SP, So CH, Rashid AJ, Varghese G, et al. (2004). Dopamine D1 and D2 receptor Co-Activation generates a novel phospholipase C-mediated calcium signal. Journal of Biological Chemistry 279, 35671-35678.
12. Luedtke RR, Griffin SA, Conroy SS, Jin X, et al. (1999). Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. Journal of Neuroimmunology 101, 170-187.
13. Ng J, Rashid AJ, So CH, O'Dowd BF, et al. (2010). Activation of calcium/calmodulin-dependent protein kinase IIalpha in the striatum by the heteromeric D1-D2 dopamine receptor complex. Neuroscience 165, 535-541.
14. Pillai A and Mahadik SP (2008). Increased truncated TrkB receptor expression and decreased BDNF/TrkB signaling in the frontal cortex of reeler mouse model of schizophrenia. Schizophrenia Research 100, 325-333.
15. Rashid AJ, So CH, Kong MM, Furtak T, et al. (2007). D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proceedings of the National Academy of Sciences USA 104, 654-659.
16. Sadri-Vakili G, Kumaresan V, Schmidt HD, Famous KR, et al. (2010). Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine. Journal of Neuroscience 30, 11735-11744.
17. Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, et al. (2009). D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Molecular Pharmacology 75, 447-453.
18. Salmanian S, Najafi SM, Rafipour M, Arjomand MR, et al. (2010). Regulation of GSK-3beta and beta-Catenin by Galphaq in HEK293 T cells. Biochemical and Biophysical Research Communications 395, 577-582.
19. So CH, Verma V, Alijaniaram M, Cheng R, et al. (2009). Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Molecular Pharmacology 75, 843-854.
20. Sutton LP and Rushlow WJ (2011). The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience 199, 116-124.
21. Weickert CS, Hyde TM, Lipska BK, Herman MM, et al. (2003). Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Molecular Psychiatry 8, 592-610.
22. Whitfield TW Jr., Shi X, Sun WL, McGinty JF (2011). The suppressive effect of an intra-prefrontal cortical infusion of BDNF on cocaine-seeking is Trk receptor and extracellular signal-regulated protein kinase mitogen-Activated protein kinase dependent. Journal of Neuroscience 31, 834-842.
23. Yoshii A, Constantine-Paton M (2007). BDNF induces transport of PSD-95 to dendrites through PI3 K-AKT signaling after NMDA receptor activation. Nature Neuroscience 10, 702-711.
24. Yu Y, Wang JR, Sun PH, Guo Y, et al. (2008). Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative action. Journal of Neurochemistry 104, 946-956.
25. Zhou Z, Hong EJ, Cohen S, Zhao WN, et al. (2006). Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52, 255-269.